Uptake and Usage Patterns of Biosimilar Infliximab in the Medicare Population

J Gen Intern Med. 2021 Jul;36(7):2170-2173. doi: 10.1007/s11606-020-05957-1. Epub 2020 Jun 23.

Authors

Steven Kozlowski¹, Natasha Flowers², Noy Birger², Michael Wernecke², Thomas E MaCurdy², Jeffrey A Kelman³, David J Graham⁴

Affiliations

¹ Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA. [email protected].
² Acumen, LLC, Burlingame, CA, USA.
³ Centers for Medicare & Medicaid Services, Washington, DC, USA.
⁴ Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.

No abstract available

Publication types

Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.

MeSH terms

Antirheumatic Agents*
Biosimilar Pharmaceuticals*
Humans
Infliximab
Medicare
Treatment Outcome
United States / epidemiology

Substances

Antirheumatic Agents
Biosimilar Pharmaceuticals
Infliximab